Ignite Creation Date:
2025-12-25 @ 1:06 AM
Ignite Modification Date:
2026-01-31 @ 5:47 PM
Study NCT ID:
NCT05243693
Status:
RECRUITING
Last Update Posted:
2022-02-17
First Post:
2022-01-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma
Sponsor:
National Cancer Center, Korea
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Relapsed/Refractory Classical Hodgkin Lymphoma | View |
Keywords: